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Abstract
Basal cell carcinoma (BCC) belongs to the group of non-melanoma skin tumors and is the most common tumor in the
western world. BCC arises due to mutations in the tumor suppressor gene Patched1 (Ptch). Analysis of the conditional Ptch
knockout mouse model for BCC reveals that macrophages and dendritic cells (DC) of the skin play an important role in BCC
growth restraining processes. This is based on the observation that a clodronate-liposome mediated depletion of these cells
in the tumor-bearing skin results in significant BCC enlargement. The depletion of these cells does not modulate Ki67 or K10
expression, but is accompanied by a decrease in collagen-producing cells in the tumor stroma. Together, the data suggest
that cutaneous macrophages and DC in the tumor microenvironment exert an antitumor effect on BCC.
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Introduction
BCC is the most commonly diagnosed tumor among people in
the western world and arises due to mutations in the tumor
suppressor gene Ptch. Although BCC rarely metastasizes it can
cause significant morbidity due to local aggressiveness and
recurrences [1]. Interestingly, approximately 20% of BCCs show
signs of spontaneous regression [2]. BCC regression is associated
with significantly increased numbers of T cells and the expression
of the IL-2 receptor, which is an early activation marker for T cells
[3]. Furthermore, a role of T-helper 1 type cytokines such as INFc,
IL-2 and TNFb has been suggested [4]. In addition, the immune
modulator imiquimod that is used for topical treatment of BCC
results in a massive peri- and intratumoral increase in macro-
phages [5].
In the skin, several types of antigen-presenting immune cells
exist. In the mouse these are mainly macrophages and DC. DC
that populate the basal and suprabasal layers of the epidermis are
often called Langerhans cells (LC), while DC in the dermis are
often called dermal DC (dDC) [6,7]. Common to these cells is the
potential to internalize particulate macromolecules and to display
migratory properties [8]. In addition, these cells can express
MHCII and/or F4/80 [6].
There is growing evidence that interactions between tumor cells
and the surrounding stroma plays an important role in tumor
progression. Several reports have demonstrated that DC including
LC are essential in the generation of an antitumor immunity in the
skin (e.g. [9,10]). Given the rich network of these cells in the skin
they are often thought to be the first immune cells to encounter
tumor antigens from cutaneous cancers (for review see [11]). This
also has been demonstrated for macrophages in extra-cutaneous
cancers where macrophages can exert a beneficial role due to
cytotoxicity to tumor cells but not to normal cells [12]. However,
high macrophage numbers also have been linked to reduced
survival of patients with solid cancers, indicating that the presence
of macrophages could also be advantageous for tumor growth and
metastasis [13]. Therefore, macrophages probably can have
contrasting roles in cancer depending on their phenotype (for
review see [14]).
Using the conditional Ptchflox/floxERT2+/2 knockout mouse
model for BCC [15], we now provide evidence that macrophages
and DC are involved in growth restraining processes in this tumor
entity.
Materials and Methods
Mice and induction of BCC
Animals were sacrificed at the indicated end points of the
experiments or if necessary due to the health conditions (e.g.
weight loss.15%, apathy) by CO2 anesthesia followed by cervical
dislocation. The mice used in the study were handled in
accordance with the German animal protection law and the
experiments were approved by the Niedersa¨chsisches Landesamt
fu¨r Verbraucherschutz und Lebensmittelsicherheit (permit num-
bers: 33.14.42502-04-026/09 and 33.14.42502-04-111/09). All
experiments using animals were performed in compliance with all
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legal and ethical requirements. Ptchflox/flox mice have loxP sites in
Ptch introns 7 and 9 [16]. Rosa26CreERT2(ERT2) mice express a
tamoxifen-inducible cre recombinase under the control of the
endogenous and ubiquitously expressed Rosa26-promoter [17].
Ptchflox/floxERT2+/2 mice were on a mixed C57BL/6 x Balb/c
background. Genotyping of the Ptchflox and the Cre-mediated
Ptchdel alleles and of ERT2 was performed as described [18]. All
primers used for genotyping are listed in Table S1.
BCCs were induced in 8 week-old conditional Ptchflox/floxERT2+/2
mice by intramuscular (i.m.) injection of 100 mg tamoxifen as
described [18,19].
Depletion of macrophages in mice using clodrolip
Liposome-encapsulated clodronate termed clodrolip was essen-
tially prepared as described previously [20]. For depletion of
macrophages in mice, clodrolip was injected intraperitoneally (i.p.)
in PtchfloxfloxERT2+/2 mice (n= 7) 15 days after tamoxifen-
mediated BCC induction. The initial clodronate dose was 2 mg/
20g body weight. Subsequently clodrolip was injected every fourth
day at a dose of 1 mg/20 g and the treatment was continued for
75 days. The same amount of empty liposomes served as a control
(n = 4). Clodrolip and empty liposomes were freshly diluted each
time in PBS to obtain the desired drug dose in 120 ml for each
animal. Animals were sacrificed 24 h after the last clodrolip or
liposome dose. Spleen and skin samples were excised. Parts of the
samples were either used for FACS analyses or RNA isolation, or
were formalin-fixed and embedded in paraffin for immunohisto-
logical analyses.
Cell culture experiments
The murine BCC cell line ASZ001 was established from UV-
induced BCC of Ptch mutant mice and was cultured as described
[21].
Cell viability/metabolic activity of ASZ001 was determined by
addition of WST-1 reagent (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s recommendations
after incubation with 0.1 mg/ml clodrolip or the same amount
of empty liposomes for 24–72 h.
FACS analyses of tissue macrophages
FACS analysis of immune cells was performed on single cell
suspensions of skin that were obtained as recently described [22].
Cells (16106) were stained with monoclonal antibodies against
Mac1 (anti CD11b-FITC, BD Biosciences #557396) and F4/80
(anti F4/80-Cy5, eBiosciences 15-4801). At least 26105 viable cells
were acquired on the basis of forward and side scattering and
quantified by using a BD LSRII cytometer. Data acquisition and
analysis were performed using the software BD FacsDiva (BD
Biosciences Pharmingen) and FlowJo (Treestar, Ashland, OR).
Gene expression analysis
Total RNA from skin was isolated using the RNeasy Fibrous
Tissue Mini Kit (Qiagen, Hilden, Germany) and cDNA was
synthesized using Superscript II and random hexamers (Invitro-
gen, Karlsruhe, Germany). Gene expression was analyzed by
SYBR-green-based qRT-PCR assays on the ABI Prism HT 7900
Detection System instrument and software (Applied Biosystems,
Darmstadt, Germany). The data was analyzed using the standard
curve method for relative quantification. All primer pairs were
intron-flanking and are shown in the Table S1. Amplification of
18S rRNA served to normalize the amount of sample cDNA. Each
sample was reverse transcribed twice and analyzed in triplicates.
The mean value of each sample was used for analysis.
Immunohistochemistry
Formalin-fixed tail skin was embedded in paraffin and sectioned
at 5 mm for histological analyses. The identity of BCC was
confirmed by examination of hematoxylin and eosin (H&E)
stained sections. The paraffin sections were stained using a
monoclonal anti-MHCII antibody (rat anti-mouse I-A/I-E
#107602 from BioLegend; for antigen retrieval boric acid was
used) that detects DC and to a lesser extend macrophages. In
addition, an anti-F4/80 antibody (rat anti mouse #MCA497GA
from Serotec; no antigen retrieval necessary) was employed that
labels macrophages and to a lesser extend DC [6]. A biotinylated
polyclonal antibody from Dako (# E0468, rabbit anti rat) served
as secondary antibody. Following incubation with Streptavidin/
HRP (#P0397, from Dako) and several washing steps, 3-Amino-9-
Ethylcarbazol was used as a substrate. For Ki67 stainings the anti-
Ki76 antibody #556003 from BD Pharmingen was used (antigen
retrieval with citrate buffer pH 6). For detection of the primary
antibody the Envision Polyclonal rabbit/mouse HRP kit (Dako,
#K5007) was used. For TUNEL staining the DeadEnd Colori-
metric TUNEL System (Promega, Germany) was applied accord-
ing to the manufacturer’s instructions. Staining was visualized with
3-Amino-9-Ethylcarbazol. After counterstaining with haematoxy-
lin the sections were covered using glycergel (Dako GmbH,
Hamburg).
MHCII+ cells were counted separately both in the epidermis
(representing LC) and the dermis (representing mostly dDC) of 7
clodrolip treated and 4 liposome treated mice. F4/80+ cells were
counted in the BCC stroma of 4 clodrolip treated and 3 liposome
treated mice. For this purpose 2 independent paraffin-embedded
skin samples (sample length and width app. 2.0 cm and 0.1 cm,
respectively) from each mouse were sectioned and positive cells
were counted on at least 3 microscopic fields of vision per sample.
The analyzed stromal or epidermal areas (at least 3.6 mm2/field of
vision or 1 mm2/field of vision, respectively) were measured using
the software cellSens Dimension (Olympus Soft Imaging Solutions
GmbH; Germany). Given are the numbers of F4/80 positive cells
per mm2 stroma and MHCII positive cells per mm2 stroma or
epidermis.
All Ki67+ cells of at least 1000 BCC cells on 2 independent
paraffin sections of 7 clodrolip treated and 4 liposome treated mice
were counted and the percentage of Ki67+ BCC cells was
calculated.
TUNEL+ BCC cells were very rare. Thus all TUNEL+ cells of 2
independent paraffin sections each of 7 clodrolip treated and 4
liposome treated mice were counted.
Goldner staining was performed to visualize components of the
connective tissue in the tumor stroma as described by Goldner
[23]. This staining labels collagen in green, cell nuclei in brownish-
red, and keratin in red color. Since most cells embedded in
collagen are fibroblasts, calculation of the number of cell nuclei
embedded in the collagen allows for quantification of fibroblasts
localized in the tumor-adjacent stroma. In order to compare the
amount of fibroblasts in liposome- and clodrolip-treated BCC-
bearing skin (n = 4 and n= 7, respectively), 16 and 23 fields of
vision (0.4 mm2 each) were analyzed, respectively. The stromal
area (in green) was measured using the software cellSens
Dimension (Olympus Soft Imaging Solutions GmbH; Germany).
Subsequently, all cellular nuclei in this region were counted and
MHCII+ and F4/80+ cells (counted on adjacent slides) were
subtracted. Given is the number of cells per mm2 stroma.
Measurement of tumor size
BCC size was measured on H&E stained sections using the area
calculation tool of the software cellSens Dimension (Olympus Soft
Clodronate Promotes BCC Growth in Mice
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Imaging Solutions GmbH; Germany). For this purpose 6
independent skin samples (each sample at app. 2.0 cm length
and 0.1 cm width) of 7 clodrolip treated and 4 liposome treated
mice were sectioned at 5 mm. The tumor area was calculated by
summing up the individual tumor area measured from each
sample and consecutive normalization to the total skin area
analyzed.
Statistical analyses
If not otherwise indicated, statistical differences were analyzed
using Mann-Whitney testing. Data was considered significant
when P,0.05.
Results
Stromal areas in BCC-bearing skin of Ptchflox/floxERT2+/2
mice are infiltrated with MHCII+ cells
We recently showed that the stroma of BCC of
Ptchflox/floxERT2+/2 mice is infiltrated with F4/80+ tumor-associ-
ated macrophages [19]. Using paraffin sections, we first confirmed
this observation and stained paraffin embedded tissue sections with
a MHCII antibody that marks dDCs and also LC in the murine
skin and to lesser extent cutaneous macrophages [6]. As shown in
Figure 1, the BCC stroma shows many MHCII+ cells, indicating
that the tumor-bearing skin is abundantly infiltrated with the
above-mentioned cell populations.
Systemic clodrolip treatment of Ptchflox/floxERT2+/2 mice
results in depletion of macrophages, dDC and LC and in
an enhancement of BCC growth
In order to determine whether the network of cutaneous DC
and macrophages are involved in growth-regulating processes in
BCC we depleted these cells in BCC-bearing Ptchflox/floxERT2+/2
mice by treating the animals with clodrolip. Empty liposomes were
used as vehicle-control. The treatment scheme was as previously
published by Zeisberger and colleagues [20] and was started 15
days after tamoxifen-mediated induction of BCC. The treatment
was continued for 75 days.
Successful macrophage depletion was first demonstrated by
reduced F4/80 immunoreactivity of the spleens of clodrolip
treated mice (Figure S1). Next we performed FACS analysis of
single cell suspensions of the skin using Mac1 and F4/80
antibodies. Whereas Mac1 is expressed on granulocytes, T-, B-
and NK-cells, DC and monocytes [24], macrophages are double
positive for Mac1 and F4/80 [25]. For the analyses 3 clodrolip-
and 3 vehicle-treated animals were sacrifized. As shown in Table 1,
the numbers of Mac1+, F4/80+ and Mac1+F4/80+ double positive
cells were generally lower in the skin of the clodrolip-treated
cohort when compared to the controls (Table 1). As also shown in
Table 1, the depletion was highly efficient in two of the clodrolip-
treated mice (mouse 2 and mouse 3 in Table 1). These results were
similar to those reported by Zeisberger and colleagues who showed
that clodrolip treatment caused depletion of F4/80+ and Mac1+
cells [20].
A reduction of F4/80+ cells in the clodrolip-treated cohort was
also revealed by immunohistochemistry (Fig. 2A). In addition,
MHCII+ cells in the BCC stroma were almost entirely depleted in
the clodrolip-treated group when compared to the vehicle-treated
group (Fig. 2B). The clodrolip-treatment also resulted in a
significant decrease in epidermal MHCII+ LC (Fig. 2B). Together
these results show that clodrolip-treatment resulted in an efficient
depletion of macrophages, dDC (i.e. DC in the dermis) and LC (i.e
DC in the basal and suprabasal layers of the epidermis). With
respect to macrophages and dDC the results are in accordance
with the current literature, which describes depletion of these cells
by clodronate. However, they are in contrast to published data
showing that LC are resistant towards the drug [26–28].
Next, we studied the effects of clodrolip on BCC growth. For
this purpose the BCC area was analyzed on H&E stained paraffin
Figure 1. MHCII expression in BCC-bearing skin of Ptchflox/floxERT2+/2 mice. H&E staining and immunohistochemical analysis of MHCII
expression on paraffin sections derived from BCC-bearing skin of Ptchflox/floxERT2+/2mice. The secondary antibody alone did not result in any staining,
hence the MHCII signals were specific (data not shown). double arrows: intraepidermal MHCII+ LC.
doi:10.1371/journal.pone.0093555.g001
Table 1. Systemic application of clodrolip decreases the
numbers of macrophages in the skin.
BCC-bearing skin
mouse Mac1+ F4/80+ Mac1+F4/80+
liposomes M1 5.98 4.30
4.40
M2 4.97 4.82 3.57
M3 3.02 3.77 2.52
mean (SEM) 4.66 (0.87) 4.30 (0.30) 3.50 (0.54)
clodrolip M1 4.69 2.41
2.38
M2 1.00 0.82 0.64
M3 1.74 0.96 0.85
mean (SEM) 2.48 (1.13) 1.40 (0.51) 1.29 (0.55)
The percentage of Mac1+, F4/80+ and Mac1+F4/80+ double-positive cells in
tumor-bearing skin of Ptchflox/floxERT2+/2 mice was determined by FACS. M1 to
M3: mouse 1 to mouse 3.
doi:10.1371/journal.pone.0093555.t001
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sections derived from 7 clodrolip- and 4 vehicle-treated mice. The
tumor area was calculated by summing up the individual tumor
area measured from each sample (see material and methods) and
normalization to the total area of the skin analyzed. The data
revealed that the BCC of the clodrolip-treated group were
significantly enlarged when compared to the vehicle-treated group
(Fig. 3A; Fig. 3B left panel). This was also obvious when
comparing the BCC size of the vehicle-treated group with that
of the 2 animals (mouse 2 and mouse 3 in Table 1) in which the
clodrolip-treatment resulted in efficient depletion of macrophages
in the skin (Fig. 3B right panel).
In order to examine whether clodrolip or empty liposomes
directly influenced tumor cell growth, we also investigated the
toxic effects of clodrolip on BCC cells in vitro. For this purpose, the
BCC cell line ASZ001 was incubated with 0.1 mg/ml clodrolip for
24 h to 72 h. The same amounts of empty liposomes or of PBS
alone were used as controls. As shown in Figure 3C clodrolip
significantly reduced the viability of ASZ001 when compared to
the controls (Fig. 3C). These data indicate that clodrolip has direct
tumoricidal activity. Therefore the tumor-promoting activity of
clodrolip in vivo might be an indirect effect of the drug on the
tumor cells.
Together these data show that macrophages and DC including
LC in BCC-bearing skin were efficiently depleted after treatment
with clodrolip. This depletion was accompanied by a significant
enhancement of tumor growth.
Clodrolip treatment of BCC-bearing skin of
Ptchflox/floxERT2+/2 mice decreases the number of
collagen-producing stromal cells
In order to analyze whether the clodrolip-mediated enhance-
ment of BCC growth was associated with a decrease in
proliferation or with increased apoptosis, we performed immuno-
histochemical analysis of the proliferation marker Ki67 and
TUNEL staining, respectively. However, neither the numbers of
Ki67+ nor of TUNEL+ cells were different between the cohorts
(Figure 4A and 4B, respectively). In addition, a first expression
analysis of the differentiation marker K10 that is solely expressed
by epidermal cells did not reveal any significant difference (data
not shown). However, we found that the clodrolip treatment
resulted in a decrease in collagen-producing stromal cells. This
became obvious by a Goldner staining (see Figure S2). As shown in
Fig 4C (left panel) the number of collagen-producing cells that are
mainly fibroblasts was significantly lower in the clodrolip-treated
cohort when compared to the liposome-treated cohort. This was in
line with qRT-PCR data showing that the expression of the
fibroblast markers vimentin and prolyl-4-hydroxylase beta (P4hb) was
decreased in the clodrolip-treated samples (Fig. 4C, middle and
right panel). Together, these data suggest that the clodrolip-
treatment, besides lowering the F4/80+ and MHCII+ cells in the
tumor microenvironment, also decreases the numbers of collagen-
producing cells, which are in all likelihood stromal fibroblasts.
Figure 2. Clodrolip treatment results in depletion of cutaneous phagocytic cells in BCC-bearing skin of Ptchflox/floxERT2+/2 mice. (A)
Immunohistochemical analysis of F4/80 expression on paraffin-sections of BCC-bearing skin derived from liposome- or clodrolip-treated Ptchflox/
floxERT2+/2 mice. Left panel shows micrographs; right panel shows the absolute number of F4/80+ cells per square millimeter of BCC-bearing tissue.
**** P,0.0001 (mean +SEM). (B) Absolute numbers of MHCII+ cells per square millimeter of BCC-bearing tissue as counted on stained paraffin-
sections from liposome- or clodrolip-treated Ptchflox/floxERT2+/2 mice. MHCII+ cells were counted separately both in the epidermis (representing LC)
and the stroma (representing DC). ** P,0.01.
doi:10.1371/journal.pone.0093555.g002
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Discussion
Our data suggest that cutaneous macrophages and DC are
necessary for tumor growth restraining processes in the
Ptchflox/floxERT2+/2 mouse model for BCC. This assumption is
based on the observations that the BCC stroma is infiltrated with
these cells and that a clodronate-liposome mediated depletion
enhances BCC growth. In addition, the clodrolip treatment was
accompanied by a decrease in collagen-producing cells. Because
the fibroblast markers vimentin and P4hb were downregulated as
well, it is likely that the respective cells were fibroblasts. The
reduction of fibroblasts was probably not a direct toxic effect of
clodronate because i) liposome-encapsuled clodronate is not
internalized by non-phagocytic cells [29] and ii) clodronate in
cell culture only marginally affects fibroblast growth [30]. Instead,
the decrease of the collagen-expressing cells might be directly
associated with the loss of macrophages that have been shown to
enhance fibroblast proliferation [31], probably by the secretion of
TNFa, PDGF or IL-1b [31,32]. However, these assumptions are
pure speculations and need more investigation in the future.
Together, our experiments demonstrate a very important role of
macrophages and DC in growth restraining processes in BCC. In
our experiments application of liposome-encapsulated clodronate
resulted in effective depletion of these cells as demonstrated by loss
of MHCII+ cells that is expressed by professional immune antigen-
presenting cells. In addition depletion of macrophages was also
demonstrated by loss of Mac1+F4/80+ cells. This is in accordance
to other reports that demonstrated elimination of DC and
macrophages upon treatment with clodronate [26,33]. We
observed a significant reduction of epidermal LC. This is in
contrast to other reports showing that LC are resistant to
clodronate [28]. However, since the skin in our setting was highly
loaded with BCC it is possible that the LC were activated and thus
phagocytosed this toxic drug at higher avidity.
The clodronate-liposome mediated loss of DC and the
accompanying enhancement of BCC growth in our model match
the established role of these cells in non-melanoma cutaneous
cancer. Thus, specific subsets of DC inclusive LC are beneficial for
tumor eradication in the skin. This is due to their ability to either
recognize, process and present foreign (tumor) antigens to T cells
or to stimulate T cell proliferation and enhance T cell activity,
respectively. In addition, DC including both LC and dDC can
produce IFN-a in response to foreign (tumor) antigens. Accord-
ingly, it has been shown that elevated amounts of dDC subsets are
indeed associated with increased clearance of BCC lesions
Figure 3. Clodrolip enhances BCC growth in Ptchflox/floxERT2+/2 mice. (A) H&E stainings of paraffin-sections derived from BCC-bearing skin of
liposome- or clodrolip-treated Ptchflox/floxERT2+/2 mice. (B) Relative tumor areas of H&E-stained BCC-bearing skin samples of liposome- or clodrolip-
treated Ptchflox/floxERT2+/2 mice. The mean value of the liposome-treated controls was normalized to 1. Left panel shows the mean value (+SEM) of all
liposome- and clodrolip-treated animals **P,0.01; right panel shows the mean value (+SEM) of all liposome-treated animals in comparison with 2
clodrolip-treated mice (mouse 2 and mouse 3 in Table 1), in which the phagocytic cells have been very efficiently depleted (due to the small sample
size, statistical analysis was omitted). (C) Viability/metabolic activity of the BCC cell line ASZ001 after treatment with PBS, liposomes or clodrolip. Mean
value of the PBS-treated controls was set to 100%. **P,0.01.
doi:10.1371/journal.pone.0093555.g003
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following treatment with imiquimod (for review see [11]). In
addition to dDC and LC, macrophages can play beneficial roles in
cancer [34]. Thus, in contrast to tumor-promoting M2 macro-
phages, these so-called M1 macrophages act by defending the host
from infections and also from tumors. Therefore, depletion of the
latter cells can result in tumor-promoting effects, which also may
have contributed to the enhancement of BCC growth in our
model as well.
In the clinics, bisphosphonates such as clodronate are frequently
used to delay the spread of bone metastases. This is due to the fact
that bisphosphonates strongly bind to mineralized bone surfaces
and are ingested by osteoclasts, wherein they inhibit osteolysis,
thereby preventing the release of growth factors from the bone
matrix [35]. In addition, bisphosphonates also revealed direct
killing of different cancer cells, including myeloma, breast cancer,
prostate cancer, and lung cancer in vitro (reviewed in [36]). Indeed,
also in our experiments the drug efficiently decreased the viability
of the BCC cell line ASZ001. Furthermore, bisphosphonates
encapsulated in nanocarriers such as liposomes can inhibit
angiogenesis and can deplete tumor-promoting macrophages,
whereas the free drug mainly inhibits osteolysis. In line with all
these effects many studies on a variety of tumors thus report that
administration of bisphosphonates generates an antitumor activity
[36]. However, despite these data there are also several reports
showing protumoral effects of clodronate administered as free drug.
For example, a study of 299 women with breast cancer
demonstrated a significantly increased rate of non-skeletal
metastases and a significantly lower overall survival rate after
clodronate therapy [37]. Furthermore, cases of esophagus
carcinoma have been described after oral bisphosphonate use
[38]. These studies show that, as in our study, clodronate can also
result in enhancement of cancerous malignancies.
In summary, in our BCC model the tumor-promoting effects of
liposome-encapsulated clodronate may result from various pro-
cesses. These include a decrease in antigen-presenting cells of the
skin (i.e. of DC including LC and macrophages), a decrease in
collagen-producing cells and most likely other so far unknown
molecular processes such as modulation of T cell numbers,
modulation of dermal angiogenesis, and the induction of a wide
palette of cytokines such as IFNc, IL-17, IL-1, IL-6, TNFa and IL-
23 that are all modulated in the skin upon treatment with
clodronate [39]. An elucidation of the exact mechanisms
underlying the tumor-promoting effects of clodrolip presented
here will be further complicated by the fact that empty liposomes
themselves can induce antitumor effects (see Figure S3) that are
likewise associated with macrophage responses such as e.g. the
induction of iNOS, Arg1 and Trem2 [22]. Nevertheless, our data
strongly suggest that macrophages and DC of the skin play an
important role in skin cancer pathogenesis in that they exert
antitumor effects on BCC, the most common tumor in humans.
Figure 4. Clodrolip decreases the number of collagen-producing cells and the mRNA expression of the fibroblast markers vimentin
and P4hb in BCC-bearing skin of Ptchflox/floxERT2+/2 mice. (A) Percentage of Ki67+ BCC cells in liposome- or clodrolip-treated Ptchflox/floxERT2+/2
mice. (B) TUNEL+ BCC cells per mm BCC-bearing skin in liposome- or clodrolip-treated Ptchflox/floxERT2+/2 mice. (C) Collagen-producing cells (mainly
fibroblast) as estimated by Goldner staining (left panel; see main manuscript for detailed informations) and qRT-PCR analysis of vimentin (middle
panel) and of P4hb (right panel) in BCC-bearing skin of Ptchflox/floxERT2+/2 mice treated with liposomes or clodrolip. Data shows the mean value
(+SEM). * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0093555.g004
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Supporting Information
Figure S1 Depletion of F4/80-expressing cells in spleens
derived from clodrolip-treated Ptchflox/floxERT2+/2mice.
Immunohistochemical analysis using an anti-F4/80 antibody of
paraffin-embedded spleens of Ptchflox/floxERT2+/2 mice treated with
empty liposomes or clodrolip.
(DOCX)
Figure S2 Evaluation of amounts of fibroblasts by the
Goldner method. The Goldner method labels collagen in green
and the nuclei and keratin in red color. Calculation of the number
of cell nuclei embedded in the collagen (in the lower panel, the
coloring of the tumor-bearing epidermis was attenuated using the
software FreeHand MX (Macromedia Inc.) to better visualize the
collagen-producing stromal cells) allows for quantification of
fibroblasts localized in the tumor-adjacent stroma. As demon-
strated by the figures, the amount of nuclei embedded in the
collagen is lower in the clodrolip-treated BCC when compared to
the liposome-treated BCC.
(DOCX)
Figure S3 Empty liposmes themselves can induce
antitumor effects in BCC-bearing Ptchflox/floxERT2+/2
mice. HE-stained skin sections of liposome-treated mice (left
panel) and PBS-treated mice (right panel). The analysis of the
tumor-bearing skin revealed that tumors of PBS-treated mice are
larger when compared to liposome-treated mice.
(DOCX)
Table S1 Oligonucleotides used for genotyping and
reverse-transcription polymerase chain reaction.
(DOCX)
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